MK-677 (Ibutamoren) vs Larazotide Acetate
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
MK-677 (Ibutamoren)Recovery & Repair
Larazotide Acetate- Summary
- MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- Half-Life
- 24 hours
- Local gut action; minimal systemic exposure
- Admin Route
- Oral
- Oral
- Research
- —
- —
- Typical Dose
- 10–25 mg
- 0.5-2 mg
- Frequency
- Once daily
- 3x daily
- Key Benefits
- Increases lean muscle mass
- Enhances bone density
- Improves sleep quality and REM sleep
- Accelerates recovery from training
- Increases appetite
- May improve skin elasticity and appearance
- Supports fat loss while maintaining muscle
- Oral administration — no injections required
- 24-hour half-life allows once-daily dosing
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Side Effects
- Increased appetite (significant in some users)
- Water retention and puffiness
- Elevated blood glucose / insulin resistance (monitor in diabetics)
- Lethargy initially
- +2 more
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Stacks With
- —
- —